Example of Drug Design, Development and Therapy format
Recent searches

Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format Example of Drug Design, Development and Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Drug Design, Development and Therapy — Template for authors

Publisher: Dove Medical Press
Categories Rank Trend in last 3 yrs
Pharmaceutical Science #39 of 166 down down by 5 ranks
Pharmacology #87 of 297 up up by 11 ranks
Drug Discovery #43 of 145 -
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 1526 Published Papers | 8499 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 06/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

American Chemical Society

Quality:  
High
CiteRatio: 6.5
SJR: 0.976
SNIP: 1.593
open access Open Access
recommended Recommended

Elsevier

Quality:  
High
CiteRatio: 7.3
SJR: 1.045
SNIP: 1.333
open access Open Access

Taylor and Francis

Quality:  
Good
CiteRatio: 4.9
SJR: 0.628
SNIP: 0.924
open access Open Access

Medknow

Quality:  
Medium
CiteRatio: 0.9
SJR: 0.234
SNIP: 0.329

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

3.216

0% from 2018

Impact factor for Drug Design, Development and Therapy from 2016 - 2019
Year Value
2019 3.216
2018 3.208
2017 2.935
2016 2.822
graph view Graph view
table view Table view

5.6

12% from 2019

CiteRatio for Drug Design, Development and Therapy from 2016 - 2020
Year Value
2020 5.6
2019 5.0
2018 5.7
2017 5.0
2016 4.1
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 0% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 12% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

0.964

10% from 2019

SJR for Drug Design, Development and Therapy from 2016 - 2020
Year Value
2020 0.964
2019 0.88
2018 0.986
2017 0.974
2016 0.993
graph view Graph view
table view Table view

1.233

18% from 2019

SNIP for Drug Design, Development and Therapy from 2016 - 2020
Year Value
2020 1.233
2019 1.048
2018 1.133
2017 0.945
2016 0.863
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 10% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 18% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Drug Design, Development and Therapy

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Dove Medical Press

Drug Design, Development and Therapy

Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design and development through to clinical applications. The journal is characterized by the rapid reporting of application notes, reviews, original res...... Read More

Pharmaceutical Science

Pharmacology

Drug Discovery

Pharmacology, Toxicology and Pharmaceutics

i
Last updated on
06 Jul 2020
i
ISSN
1177-8881
i
Impact Factor
High - 1.394
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
Blue faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
unsrt
i
Citation Type
Numbered
[25]
i
Bibliography Example
C. W. J. Beenakker. Specular andreev reflection in graphene. Phys. Rev. Lett., 97(6):067007, 2006.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.2147/DDDT.S119488
Metal complexes in cancer therapy - an update from drug design perspective.
Umar Ndagi1, Ndumiso N. Mhlongo1, Mahmoud E. S. Soliman1

Abstract:

In the past, metal-based compounds were widely used in the treatment of disease conditions, but the lack of clear distinction between the therapeutic and toxic doses was a major challenge. With the discovery of cisplatin by Barnett Rosenberg in 1960, a milestone in the history of metal-based compounds used in the treatment of... In the past, metal-based compounds were widely used in the treatment of disease conditions, but the lack of clear distinction between the therapeutic and toxic doses was a major challenge. With the discovery of cisplatin by Barnett Rosenberg in 1960, a milestone in the history of metal-based compounds used in the treatment of cancers was witnessed. This forms the foundation for the modern era of the metal-based anticancer drugs. Platinum drugs, such as cisplatin, carboplatin and oxaliplatin, are the mainstay of the metal-based compounds in the treatment of cancer, but the delay in the therapeutic accomplishment of other metal-based compounds hampered the progress of research in this field. Recently, however, there has been an upsurge of activities relying on the structural information, aimed at improving and developing other forms of metal-based compounds and nonclassical platinum complexes whose mechanism of action is distinct from known drugs such as cisplatin. In line with this, many more metal-based compounds have been synthesized by redesigning the existing chemical structure through ligand substitution or building the entire new compound with enhanced safety and cytotoxic profile. However, because of increased emphasis on the clinical relevance of metal-based complexes, a few of these drugs are currently on clinical trial and many more are awaiting ethical approval to join the trial. In this review, we seek to give an overview of previous reviews on the cytotoxic effect of metal-based complexes while focusing more on newly designed metal-based complexes and their cytotoxic effect on the cancer cell lines, as well as on new approach to metal-based drug design and molecular target in cancer therapy. We are optimistic that the concept of selective targeting remains the hope of the future in developing therapeutics that would selectively target cancer cells and leave healthy cells unharmed. read more read less
View PDF
604 Citations
open accessOpen access Journal Article DOI: 10.2147/DDDT.S165440
Current development of biodegradable polymeric materials for biomedical applications
Richard Song1, Maxwell Murphy1, Chenshuang Li1, Kang Ting1, Chia Soo1, Zhong Zheng1

Abstract:

In the last half-century, the development of biodegradable polymeric materials for biomedical applications has advanced significantly. Biodegradable polymeric materials are favored in the development of therapeutic devices, including temporary implants and three-dimensional scaffolds for tissue engineering. Further advancemen... In the last half-century, the development of biodegradable polymeric materials for biomedical applications has advanced significantly. Biodegradable polymeric materials are favored in the development of therapeutic devices, including temporary implants and three-dimensional scaffolds for tissue engineering. Further advancements have occurred in the utilization of biodegradable polymeric materials for pharmacological applications such as delivery vehicles for controlled/sustained drug release. These applications require particular physicochemical, biological, and degradation properties of the materials to deliver effective therapy. As a result, a wide range of natural or synthetic polymers able to undergo hydrolytic or enzymatic degradation is being studied for biomedical applications. This review outlines the current development of biodegradable natural and synthetic polymeric materials for various biomedical applications, including tissue engineering, temporary implants, wound healing, and drug delivery. read more read less
View PDF
522 Citations
open accessOpen access Journal Article DOI: 10.2147/DDDT.S97635
Eteplirsen in the treatment of Duchenne muscular dystrophy
Kenji Rowel Q. Lim1, Rika Maruyama1, Toshifumi Yokota2

Abstract:

Duchenne muscular dystrophy is a fatal neuromuscular disorder affecting around one in 3,500-5,000 male births that is characterized by progressive muscular deterioration. It is inherited in an X-linked recessive fashion and is caused by loss-of-function mutations in the DMD gene coding for dystrophin, a cytoskeletal protein t... Duchenne muscular dystrophy is a fatal neuromuscular disorder affecting around one in 3,500-5,000 male births that is characterized by progressive muscular deterioration. It is inherited in an X-linked recessive fashion and is caused by loss-of-function mutations in the DMD gene coding for dystrophin, a cytoskeletal protein that stabilizes the plasma membrane of muscle fibers. In September 2016, the US Food and Drug Administration granted accelerated approval for eteplirsen (or Exondys 51), a drug that acts to promote dystrophin production by restoring the translational reading frame of DMD through specific skipping of exon 51 in defective gene variants. Eteplirsen is applicable for approximately 14% of patients with DMD mutations. This article extensively reviews and discusses the available information on eteplirsen to date, focusing on pharmacological, efficacy, safety, and tolerability data from preclinical and clinical trials. Issues faced by eteplirsen, particularly those relating to its efficacy, will be identified. Finally, the place of eteplirsen and exon skipping as a general therapeutic strategy in Duchenne muscular dystrophy treatment will be discussed. read more read less

Topics:

Eteplirsen (86%)86% related to the paper, Duchenne muscular dystrophy (66%)66% related to the paper, Exon skipping (60%)60% related to the paper, Dystrophin (53%)53% related to the paper
View PDF
469 Citations
open accessOpen access Journal Article DOI: 10.2147/DDDT.S99651
Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery.
Tarek A. Ahmed1, Bader M Aljaeid1

Abstract:

Naturally occurring polymers, particularly of the polysaccharide type, have been used pharmaceutically for the delivery of a wide variety of therapeutic agents. Chitosan, the second abundant naturally occurring polysaccharide next to cellulose, is a biocompatible and biodegradable mucoadhesive polymer that has been extensivel... Naturally occurring polymers, particularly of the polysaccharide type, have been used pharmaceutically for the delivery of a wide variety of therapeutic agents. Chitosan, the second abundant naturally occurring polysaccharide next to cellulose, is a biocompatible and biodegradable mucoadhesive polymer that has been extensively used in the preparation of micro-as well as nanoparticles. The prepared particles have been exploited as a potential carrier for different therapeutic agents such as peptides, proteins, vaccines, DNA, and drugs for parenteral and nonparenteral administration. Therapeutic agent-loaded chitosan micro- or nanoparticles were found to be more stable, permeable, and bioactive. In this review, we are highlighting the different methods of preparation and characterization of chitosan micro- and nanoparticles, while reviewing the pharmaceutical applications of these particles in drug delivery. Moreover, the roles of chitosan derivatives and chitosan metal nanoparticles in drug delivery have been illustrated. read more read less

Topics:

Drug delivery (56%)56% related to the paper, Chitosan (56%)56% related to the paper, Drug carrier (55%)55% related to the paper
View PDF
453 Citations
open accessOpen access Journal Article DOI: 10.2147/DDDT.S56071
Animal models of ischemic stroke and their application in clinical research.

Abstract:

This review outlines the most frequently used rodent stroke models and discusses their strengths and shortcomings Mimicking all aspects of human stroke in one animal model is not feasible because ischemic stroke in humans is a heterogeneous disorder with a complex pathophysiology The transient or permanent middle cerebral art... This review outlines the most frequently used rodent stroke models and discusses their strengths and shortcomings Mimicking all aspects of human stroke in one animal model is not feasible because ischemic stroke in humans is a heterogeneous disorder with a complex pathophysiology The transient or permanent middle cerebral artery occlusion (MCAo) model is one of the models that most closely simulate human ischemic stroke Furthermore, this model is characterized by reliable and well-reproducible infarcts Therefore, the MCAo model has been involved in the majority of studies that address pathophysiological processes or neuroprotective agents Another model uses thromboembolic clots and thus is more convenient for investigating thrombolytic agents and pathophysiological processes after thrombolysis However, for many reasons, preclinical stroke research has a low translational success rate One factor might be the choice of stroke model Whereas the therapeutic responsiveness of permanent focal stroke in humans declines significantly within 3 hours after stroke onset, the therapeutic window in animal models with prompt reperfusion is up to 12 hours, resulting in a much longer action time of the investigated agent Another major problem of animal stroke models is that studies are mostly conducted in young animals without any comorbidity These models differ from human stroke, which particularly affects elderly people who have various cerebrovascular risk factors Choosing the most appropriate stroke model and optimizing the study design of preclinical trials might increase the translational potential of animal stroke models read more read less

Topics:

Stroke (63%)63% related to the paper
View PDF
451 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Drug Design, Development and Therapy.

It automatically formats your research paper to Dove Medical Press formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Drug Design, Development and Therapy format uses unsrt citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Drug Design, Development and Therapy in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Drug Design, Development and Therapy guidelines and auto format it.

2. Do you follow the Drug Design, Development and Therapy guidelines?

Yes, the template is compliant with the Drug Design, Development and Therapy guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Drug Design, Development and Therapy?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Drug Design, Development and Therapy citation style.

4. Can I use the Drug Design, Development and Therapy templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Drug Design, Development and Therapy.

5. Can I use a manuscript in Drug Design, Development and Therapy that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Drug Design, Development and Therapy that you can download at the end.

6. How long does it usually take you to format my papers in Drug Design, Development and Therapy?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Drug Design, Development and Therapy.

7. Where can I find the template for the Drug Design, Development and Therapy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Drug Design, Development and Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Drug Design, Development and Therapy's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Drug Design, Development and Therapy an online tool or is there a desktop version?

SciSpace's Drug Design, Development and Therapy is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Drug Design, Development and Therapy?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Drug Design, Development and Therapy?”

11. What is the output that I would get after using Drug Design, Development and Therapy?

After writing your paper autoformatting in Drug Design, Development and Therapy, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Drug Design, Development and Therapy's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Drug Design, Development and Therapy?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Drug Design, Development and Therapy. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Drug Design, Development and Therapy?

The 5 most common citation types in order of usage for Drug Design, Development and Therapy are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Drug Design, Development and Therapy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Drug Design, Development and Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Drug Design, Development and Therapy in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Drug Design, Development and Therapy Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Drug Design, Development and Therapy formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template